Keywords: avax, melanoma, vaccine, technologies, recieved, go-ahead, usa

AVAX' Melanoma Vaccine

Article | 30 July 1998

Print This

AVAX Technologies has recieved the go-ahead in the USA to begin apivotal trial of M-Vax, its experimental autologous vaccine for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in